

Table S1. Cytotoxicity and antiviral activity of Essential oils and reference compounds against representatives of ssRNA⁺ (HIV-1, BVDV, DENV-2, WNV, YFV, CV-B5, Sb-1), ssRNA⁻ (RSV, VSV), and dsDNA (VV, HSV-1) viruses.

Compds	MT-4	HIV-1	MDBK	BVDV	BHK	DENV-2	WNV	YFV	Vero76	CV-B5	Sb-1	RSV	VSV	VV	HSV-1
	^a CC ₅₀	^b EC ₅₀	^c CC ₅₀	^d EC ₅₀	^e CC ₅₀	^f EC ₅₀	^g EC ₅₀	^h EC ₅₀	ⁱ CC ₅₀	^j EC ₅₀	^k EC ₅₀	^l EC ₅₀	^m EC ₅₀	ⁿ EC ₅₀	^o EC ₅₀
<i>Lavandula angustifolia</i>	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
<i>Foeniculum vulgare</i>	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	100	>100	>100	>100	>100
<i>Salvia officinalis</i>	>100	>100	>100	50±3	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
<i>Myrtus communis</i>	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
<i>Pistacia lentiscus</i>	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
<i>Eucalyptus globulus</i>	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
<i>Laurus nobilis</i>	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100	>100
<i>Helichrysum italicum ssp. microphyllum</i>	>100	>100	>100	>100	>100	>100	>100	>100	≥100	>100	>100	>100	>100	>100	>100
<i>Satureja thymbra</i>	>100	>100	>100	>100	>100	>100	>100	>100	≥100	>100	>100	>100	>100	>100	>100
*Reference Compounds															
Efavirenz	40	0.002													
Pleconaril									>100	0.005					
2'-C-Me-Gua			>100	1.6	60.0	0.3	0.4	1.2							
6-Aza-Uridine									4.0			1.0			
Mycophen.Ac.									20					1.5	
AcycloGuo															

- ^a Compd concn (µg/ml) required to reduce by 50 % the proliferation of mock-infected MT-4 cells, as determined by the MTT method.
- ^b Compd concn (µg/ml) required to achieve 50 % protection of MT-4 cells from HIV-1-induced cytopathogenicity, as determined by the MTT method.
- ^c Compd concn (µg/ml) required to reduce by 50 % the viability of mock-infected MDBK cells, as determined by the MTT method.
- ^d Compd concn (µg/ml) required to achieve 50 % protection of MDBK cells from BVDV-induced cytopathogenicity, as determined by the MTT method.
- ^e Compd concn (µg/ml) required to reduce by 50 % the viability of mock-infected BHK cells, as determined by the MTT method.
- ^{f-h} Compd concn (µg/ml) required to achieve 50 % protection of BHK cells from DENV-2^(f)-, WNV^(g)-, YFV^(h)-induced cytopathogenicity, as determined by the MTT method.
- ⁱ Compd concn (µg/ml) required to reduce by 50 % the viability of mock-infected Vero-76 cells, as determined by the MTT method.
- ^{j-o} Compd concn (µg/ml) required to reduce by 50 % the plaque number of CV-B5^(j), Sb-1^(k), RSV^(l), VSV^(m), VV⁽ⁿ⁾, HSV-1^(o) in Vero-76 cells.
- *Reference Compounds (µM)